• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

XOMA

edit

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people’s lives.

Recent Milestones

edit

• 
  XOMA — Xoma snags $505 million pact on its top drug prospect (1/4/11)
  Posted 1/16/11 at 10:49pm via fiercebiotech.com
• 
  XOMA added Steven B. Engle as Chairman and CEO.
  Posted 9/6/10 at 8:08pm
• 
  XOMA added Jack Wyszomierski as Board of directors.
  Posted 9/6/10 at 8:08pm

Videos

Screenshots

edit

Sources

Xoma snags $505 million pact on its top drug prospect (fiercebiotech.com) [edit]